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Antibiotic-resistant pathogens are a global health threat. Small molecules that inhibit bacterial 
virulence have been suggested as alternatives or adjuncts to conventional antibiotics, as they may 
limit pathogenesis and increase bacterial susceptibility to host killing. Staphylococcus aureus is a 
major cause of invasive skin and soft tissue infections (SSTIs) in both the hospital and 
community settings, and it is also becoming increasingly antibiotic resistant. Quorum sensing 
(QS) mediated by the accessory gene regulator (agr) controls virulence factor production 
essential for causing SSTIs. We recently identified ω-hydroxyemodin (OHM), a 
polyhydroxyanthraquinone isolated from solid-phase cultures of Penicillium restrictum, as a 
suppressor of QS and a compound sought for the further characterization of the mechanism of 
action. At concentrations that are nontoxic to eukaryotic cells and subinhibitory to bacterial 
growth, OHM prevented agr signaling by all four S. aureus agr alleles. OHM inhibited QS by 
direct binding to AgrA, the response regulator encoded by the agr operon, preventing the 
interaction of AgrA with the agr P2 promoter. Importantly, OHM was efficacious in a mouse 
model of S. aureus SSTI. Decreased dermonecrosis with OHM treatment was associated with 
enhanced bacterial clearance and reductions in inflammatory cytokine transcription and 
expression at the site of infection. Furthermore, OHM treatment enhanced the immune cell 
killing of S. aureus in vitro in an agr-dependent manner. These data suggest that bacterial 
disarmament through the suppression of S. aureus QS may bolster the host innate immune 
response and limit inflammation. 
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Antibiotic-resistant pathogens are a global health threat. Small molecules that inhibit bacterial virulence have been suggested as
alternatives or adjuncts to conventional antibiotics, as they may limit pathogenesis and increase bacterial susceptibility to host
killing. Staphylococcus aureus is a major cause of invasive skin and soft tissue infections (SSTIs) in both the hospital and com-
munity settings, and it is also becoming increasingly antibiotic resistant. Quorum sensing (QS) mediated by the accessory gene
regulator (agr) controls virulence factor production essential for causing SSTIs. We recently identified -hydroxyemodin
(OHM), a polyhydroxyanthraquinone isolated from solid-phase cultures of Penicillium restrictum, as a suppressor of QS and a
compound sought for the further characterization of the mechanism of action. At concentrations that are nontoxic to eukaryotic
cells and subinhibitory to bacterial growth, OHM prevented agr signaling by all four S. aureus agr alleles. OHM inhibited QS by
direct binding to AgrA, the response regulator encoded by the agr operon, preventing the interaction of AgrA with the agr P2
promoter. Importantly, OHM was efficacious in a mouse model of S. aureus SSTI. Decreased dermonecrosis with OHM treat-
ment was associated with enhanced bacterial clearance and reductions in inflammatory cytokine transcription and expression at
the site of infection. Furthermore, OHM treatment enhanced the immune cell killing of S. aureus in vitro in an agr-dependent
manner. These data suggest that bacterial disarmament through the suppression of S. aureus QS may bolster the host innate
immune response and limit inflammation.
Due to the widespread and seemingly inevitable developmentof bacterial resistance to antibiotics shortly after their intro-
duction, there is a great need for alternatives or adjuncts to classi-
cal antimicrobials (1–3). Along with ongoing efforts to identify
novel antibacterial targets, interventions that are not directly bac-
tericidal may prove efficacious. These include approaches aimed
at modifying or augmenting the host response, as well as ap-
proaches that inhibit bacterial virulence mechanisms and thus
limit pathogenesis (1–3). Many pathogenic bacteria coordinate
the expression of virulence factors important for invasive infec-
tion and pathogenesis through a density-dependent communica-
tion system called quorum sensing (QS) (4, 5). Therefore,
approaches aimed at disrupting QS hold promise to limit patho-
genesis in the host and/or serve as adjuncts to extend the utility of
existing antibiotics (4, 6–10).
Skin and soft tissue infections (SSTIs) represent the majority of
infections caused by Staphylococcus aureus (11–13), and many of
the virulence factors contributing to SSTIs are globally regulated
by the accessory gene regulator (agr) (Fig. 1A) (14–16). The agr
system utilizes a small secreted autoinducing peptide (AIP) to
activate a receptor histidine kinase, AgrC, in the bacterial cell
membrane. AgrC phosphorylates the transcription factor AgrA,
which in turn activates transcription at the P2 and P3 promoters
of the operon. P3 activation drives the production of the effector
of the operon, RNAIII, which regulates the expression of 200
virulence genes that contribute to invasive infection (14). S. aureus
isolates have one of four agr alleles (agr-I to agr-IV), each encod-
ing factors that secrete a unique AIP (AIP1 to AIP4, respectively)
that is detected by a cognate AgrC histidine kinase; isolates from
each allele can cause human disease (17, 18). Importantly, we and
others have shown that the disruption of agr signaling by mu-
tagenesis, monoclonal antibodies, or host factors limits S. aureus
infection and reduces pathogenesis (14, 19–24), demonstrating
that agr QS is a robust target for combating invasive S. aureus
infection.
Recently, we reported on a synthetic small-molecule inhibitor
of S. aureus QS called savirin, providing proof of principle that
small-molecule-mediated inhibition of QS can be efficacious
against S. aureus in vivo (25). Natural products also represent a
wealth of bioactive compounds, as approximately 65% of the an-
tibacterials introduced in the last 30 years are natural products or
compounds designed based on a lead natural-product pharmaco-
phore (26). Therefore, we extended our search for inhibitors of QS
to natural products and in doing so identified a series of polyhy-
droxyanthraquinones isolated from cultures of the fungus Peni-
cillium restrictum that inhibited S. aureus QS (27). Among these,
-hydroxyemodin (OHM) (Fig. 1B) demonstrated the most po-
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tent activity for inhibiting agr-I signaling. Therefore, we sought to
characterize OHM as an inhibitor of agr signaling and to evaluate
its efficacy in vivo.
Approaches aimed at augmenting the host response and those
aimed at inhibiting bacterial virulence mechanisms provide alter-
natives to conventional antibiotic therapy. However, these two
approaches are not mutually exclusive, and because many S.
aureus virulence factors antagonize the host innate immune re-
sponse, we proposed that inhibiting bacterial virulence would
itself augment host defense. Specifically, we postulated that small-
molecule-mediated disruption of S. aureus QS-dependent viru-
lence would not only limit pathogenesis but would also reduce
inflammation and result in enhanced bacterial clearance. Here, we
report that OHM inhibits S. aureus QS by isolates from all four agr
alleles at concentrations that are noncytotoxic to S. aureus or eu-
karyotic cells. Mechanistically, OHM inhibits agr activation by
binding directly to AgrA and blocking binding to agr promoter
DNA. Importantly, as predicted, OHM limits tissue damage and
inflammation and promotes bacterial clearance in a mouse model
of S. aureus SSTI. In addition, OHM promotes the killing of agr,
but not agr-negative, S. aureus by both mouse macrophages and
human polymorphonuclear leukocytes (PMNs), and it limits neu-
trophil lysis caused by agr-regulated S. aureus-secreted virulence
factors. This is the first report of a polyhydroxyanthraquinone
with in vivo efficacy against S. aureus QS-dependent virulence. In
addition, these data demonstrate that antivirulence approaches
can limit disease by disarming the bacteria while concurrently
bolstering host innate defense.
MATERIALS AND METHODS
Ethics statements. The animal work in this study was carried out in strict
accordance with the recommendations in the Guide for the Care and Use of
Laboratory Animals (97), the Animal Welfare Act, and U.S. federal law.
The protocol was approved by the Institutional Animal Care and Use
Committee of the University of New Mexico Health Sciences Center. The
polymorphonuclear cells were isolated from whole blood samples from
consenting healthy human volunteers, according to the protocol (no. 11-
005) approved by the Human Research Protections Office of the Univer-
sity of New Mexico institutional review board.
Bacterial strains and growth conditions. Methicillin-resistant S. au-
reus (MRSA) strain USA300 LAC (agr-I) was provided as a generous gift
from Frank DeLeo (Rocky Mountain National Laboratories, National In-
stitutes of Health, Hamilton, MT). S. aureus strains AH1677 (agr-I),
AH430 (agr-II), AH1747 (agr-III), and AH1872 (agr-IV) expressing yel-
low fluorescent protein (YFP) under the control of the agr::P3 promoter
were previously described (28). Staphylococcus epidermidis strain AH3408
(agr-I) expressing superfolder green fluorescent protein (sGFP) under the
control of the agr::P3 promoter was also previously described (29). S.
aureus strains AH3469 (AgrC wild type [WT]) and AH3470 (AgrC
R238H) are described below. Unless otherwise noted, the bacteria were
cultured at 37°C and 220 rpm, with at least a 5:1 air-to-culture ratio in
Trypticase soy broth (TSB) (Becton, Dickinson and Company, Sparks,
MD). Early exponential-phase bacteria were prepared as described previ-
ously (30). The frozen stocks were maintained at 80°C in TSB supple-
mented with 10% glycerol. The bacteria were enumerated by serial dilu-
tion and plating onto Trypticase soy agar containing 5% sheep blood
(Becton, Dickinson and Company), followed by overnight incubation at
37°C. The limit of detection was 2 log10 CFU.
agr::P3 promoter activation assays. Overnight cultures of S. aureus
agr::P3 reporter strains were grown in TSB supplemented with 10 g/ml
chloramphenicol (Cam). The cultures were diluted 1:250 into fresh TSB
with Cam, and 100-l aliquots were transferred to 96-well microtiter
plates (Costar 3603; Corning, Tewksbury, MA) prefilled with 100 l of
medium and a 2-fold serial dilution series (200 to 0.1 M) of OHM. OHM
was purified from solid-phase cultures of P. restrictum, as described pre-
viously (27), and was 95% pure, as measured by ultrahigh-performance
liquid chromatography (UPLC) (see Fig. S1 in the supplemental mate-
rial). After mixing in the microtiter plate, the effective dilution was 1:500,
and the final OHM concentration ranged from 100 to 0.05 M, with a
final dimethyl sulfoxide (DMSO) concentration of 0.1% (vol/vol) in all
wells. Four dilution series were prepared for each reporter; in addition, 4
mock DMSO dilution series were included for each reporter strain. The
microtiter plates were incubated at 37°C with shaking (1,000 rpm) in a
Stuart SI505 incubator (Bibby Scientific, Burlington, NJ) with a humidi-
fied chamber. Fluorescence (top reading of 493 nm excitation, 535 nm
emission, and gain of 60) and optical density at 600 nm (OD600) readings
were recorded at 30-min increments using a Tecan Systems (San Jose, CA)
Infinite M200 plate reader.
S. epidermidis AH3408 (agr-I::P3-sGFP) was cultured overnight in
TSB supplemented with 10 g/ml erythromycin (Erm). To collect exog-
enous S. epidermidis AIP1 peptide, the spent medium was centrifuged at
3,000  g, passed through a 0.2-m HT Tuffryn membrane (Pall, Port
Washington, NY), and stored at 20°C until use. An overnight culture of
FIG 1 (A) Schematic of the S. aureus accessory gene regulator quorum-sens-
ing system and structure of -hydroxyemodin. 1, The agr P2 promoter drives
the expression of the four genes of the operon agrBDCA. 2, AgrD is a propep-
tide that is cyclized to form autoinducing peptide (AIP) and secreted via AgrB.
AIPs from the four agr alleles vary in length from seven to nine amino acids,
but all contain a five-membered thiolactone ring. 3, Secreted AIP binds to its
cognate receptor AgrC, activating its histidine kinase function leading to the
phosphorylation of AgrA. 4, AgrA binds to the divergent promoters P2 and P3
as well as the promoters for the transcription of the phenol-soluble modulin
(PSM) toxins. 5, P2 drives a positive-feedback loop resulting in the upregula-
tion of the agr operon, whereas P3 drives the transcription of the effector
molecule RNAIII. RNAIII leads to the upregulation of virulence factors that
contribute to invasive infection. (B) Structure of -hydroxyemodin (OHM).
Molecular mass, 286.24 Da.
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AH3408 was diluted 1:200 into 500 l of TSB (broth) or TSB with 10%
spent medium containing 5 g/ml OHM or DMSO (vehicle). The cul-
tures were incubated for 24 h at 37°C, centrifuged, and resuspended in
10% formalin fixative for 1 min. The cultures were washed twice by
centrifugation and resuspended in phosphate-buffered saline (PBS). The
mean channel fluorescence (MCF) of sGFP was analyzed using an Accuri
C6 flow cytometry system (BD Biosciences, San Jose, CA). The data were
normalized to the broth cultures containing no exogenous AIP1.
Quantitative PCR. For transcriptional quantification of mouse
mRNA, 2.25-cm2 sections of skin including and surrounding the abscess
were excised, minced, and stored in RNAlater (Qiagen, Valencia, CA) at
20°C until use. mRNA was purified using the RNeasy kits (Qiagen), and
cDNA was generated using a high-capacity RNA-to-cDNA kit (Applied
Biosystems, Foster City, CA). Quantitative PCR was performed using an
ABI 7900HT real-time PCR system with TaqMan Gene expression master
mix, according to the manufacturer’s directions (Applied Biosystems).
Predesigned primer and probe sets (Integrated DNA Technologies, Cor-
alville, IA) were used for the quantitation of mouse il-6, il-1, tnf	, nlrp3,
and hprt. The data are represented as the fold increase relative to hprt
compared to that in uninfected tissue.
For the quantification of S. aureus gene transcription, 500-l cultures
at 2  107 CFU/ml of LAC and/or LAC
agr were grown in TSB at 37°C,
with aeration, for the indicated times with 50 nM exogenous AIP1 (Bio-
peptide Co., Inc., San Diego, CA) and treatments (vehicle versus OHM),
as indicated in the appropriate figure legends. The bacteria were stored at
20°C in RNAprotect cell reagent, according to the manufacturer’s rec-
ommendations (Qiagen), until the RNA was purified as previously de-
scribed (25). cDNA generation and quantitative PCR (qPCR) were per-
formed as described above for eukaryotic qPCR. The primer and probe
sets for the quantification of the S. aureus genes are listed in Table S1 in the
supplemental material.
Rabbit red blood cell lysis assay. The assay was performed as previ-
ously described (31). Briefly, LAC was cultured in 5 ml of TSB for 8 h with
the indicated treatments, centrifuged, and the supernatants were filtered
through a 0.2-m HT Tuffryn membrane (Pall). Serial 2-fold dilutions of
the supernatant were incubated at 37°C for 1 h in a 4% solution of rabbit
red blood cells (rRBCs). Lysis was assessed spectrophotometrically at
OD450. The data were analyzed by nonlinear regression fit to a four-
parameter logistic curve and represented as the HA50, which equals 1/the
dilution required for 50% complete lysis.
AgrC constitutive reporter assay. The agrBDCA operon was ampli-
fied from strain LAC using the primers AgrBRBS 5=–KpnI (GTTGGTA
CCCAGTGAGGAGAGTGGTGTAAAATTG) and AgrA 3=-SacI (GTTGA
GCTCCTTATTATATTTTTTTAACGTTTCTCACCGATG) and ligated
into pRMC2 (32). To make a variant with constitutive AgrC activity, we
chose the AgrC R238H mutation, which was previously shown to have
similar activity in the presence and absence of the AIP2 inhibitor and
maximal activity in the absence of AIP1 (33). The AgrC R238H variant
was generated by the QuikChange (Agilent Technologies) site-directed
mutagenesis method, using the primers AgrC R238H fwd (CAACGAAA
TGCGCAAGTTCCATCATGATTATGTCAATATC) and AgrC R238H
rev (GATATTGACATAATCATGATGGAACTTGCGCATTTCGTTG).
To build a destination strain for assessing alpha-hemolysin production,
we selected an agrC transposon mutant (NE873) from the Nebraska
Transposon Mutant Library (34) and integrated the pLL29 plasmid at the
phage 11 attachment site to confer tetracycline resistance (35). The above-
described pRMC2 constructs were transformed into this strain to make
reporters AH3469 (AgrC WT) and AH3470 (AgrC R238H). To test OHM,
AH3469 and AH3470 were grown overnight with 10 g/ml Cam and were
diluted 1:500 into 5 ml of fresh medium with 10 g/ml Cam and 0.025
g/ml anhydrotetracycline. AIP2 control, OHM, or DMSO (vehicle) was
added to each strain at the concentrations indicated. The cultures were
grown at 37°C and shaken at 220 rpm for 6.5 h. The bacteria were pelleted
by centrifugation, and the alpha-hemolysin-containing supernatants
were passed through a 0.2-m HT Tuffryn membrane (Pall). Rabbit red
blood cell lysis assays were conducted as above but with an rRBC concen-
tration of 1% and 25% supernatant (vol/vol) to yield complete lysis. The
values are presented as the mean relative lysis compared to that with
vehicle treatment.
Eukaryotic cytotoxicity. A549, HEK293, or HepG2 cells were seeded
in a 96-well tissue culture plate at 2.5  104 cells per well and incubated at
37°C with 5% CO2. XTT [2,3-Bis(2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide] and phenazine methosulfate (PMS)
were purchased from Sigma-Aldrich (St. Louis, MO). The XTT assay was
previously described (36). After 24 h, the spent medium was removed, and
fresh medium containing the indicated drug concentrations or vehicle
was added to the cells and incubated for an additional 24 h. To avoid
potential interference with the absorbance readings due to the red color of
OHM, drug-containing medium was replaced with 100 l of 0.3 mg/ml
XTT with 0.015 mg/ml PMS in Hanks’ balanced salt solution (HBSS) and
incubated for 1 h. Cell viability was assessed by the metabolic reduction of
tetrazolium measured at OD490. The data are presented as the percentage
of viable cells compared to that in the vehicle control.
EMSA and flow cytometry-based AgrAC promoter binding assays.
Escherichia coli expressing the AgrA C-terminal DNA binding domain
(AgrAC) along with a 6-histidine tag was generously provided by Chuan
He (University of Chicago, Chicago, IL) and purified as previously de-
scribed (37). Electrophoretic mobility shift assays (EMSA) were per-
formed as previously described (25), with purified AgrAC and agr P2 pro-
moter, and a 16-bp duplex DNA probe with a 3= 6-fluorescein (P2-FAM)
(Integrated DNA Technologies, Coralville, IA). The duplex DNA con-
tained the high-affinity LytTR binding site located in both agr P2 and P3
promoters (38). Briefly, 2 M AgrAC was incubated for 10 min at room
temperature (RT) with vehicle or the indicated concentrations of OHM in
Tris-acetate-EDTA (TAE) buffer with 10 mM dithiothreitol (DTT). Next,
20 ng of P2-FAM DNA probe was added and incubated for an additional
10 min. The reaction mixtures were loaded onto a 10% PAGE gel and run
at 50 V in the dark for 20 min. DNA migration was assessed by imaging on
a FluorChem R system (ProteinSimple, Santa Clara, CA).
For the flow-based AgrAC promoter binding assays, AgrAC was bio-
tinylated (AgrAC-BTN) using a Thermo Scientific EZ-Link sulfo-NHS-
LC-biotin kit (Thermo Scientific, Rockford, IL), according to the manu-
facturer’s directions. AgrAC-BTN was immobilized on 1-m-diameter
Dynabeads MyOne streptavidin T1 (Life Technologies, Grand Island,
NY) (AgrAC-SA), and the beads were suspended in PBS. DNA probe
(P2-FAM) was added at a final concentration of 1.6 M, along with
equimolar competing unlabeled P2, vehicle control, or OHM at the indi-
cated concentrations. OHM-mediated inhibition of AgrAC-SA binding to
DNA probe was measured as decreased mean channel fluorescence
(MCF) compared to that of the vehicle control using an Accuri C6 flow
cytometry system (BD Biosciences).
In silico docking on AgrAC. In silico docking calculations were per-
formed using the Macintosh binary executable of AutoDock Vina (39).
OHM was docked onto the B subunit of the AgrAC crystal structure
(RSCB Protein Data Bank [www.pdb.org], PDB ID 4G4K) (40, 41)
stripped of heteroatoms. The search box was restricted to the C-terminal
region of AgrAC, as described for 9H-xanthene-9-carboxylic acid (40).
Based on initial observations suggesting that OHM bound to the pocket
between the side chains of His200, Agr218, Tyr229, and Val232, addi-
tional calculations were run in which the size of search box was varied and
the side-chain torsion angles for different combinations of residues in the
region were allowed to be flexible. The reported docking solution was
obtained by allowing flexibility in the side chain torsion angles for His200,
Agr218, Tyr229, and Val232 and by using a search box that was large
enough to include both the pocket bounded by the side chains of His200,
Agr218, Tyr229, and Val232 and the groove between Val232 and Lys236.
Molecular modeling images were prepared using PDB ID 3BS1 and
PyMOL (PyMOL molecular graphics system, version 1.5.0.4; Schro-
dinger, LLC).
Natural Product Limits of S. aureus Virulence
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Surface plasmon resonance analysis. To overcome the potential in-
terference for the oxidative inactivation of AgrAC during surface plasmon
resonance (SPR) analysis, the oxidation-resistant C199S mutation was
introduced into the AgrAC expression construct, as previously described
(37), using the QuikChange II XL kit (Agilent Technologies). His-tagged
AgrAC-C199S was purified as described previously (25) but without the
addition of Tris(2-carboxyethyl)phosphine (TCEP) or DTT during puri-
fication.
SPR binding and kinetics analyses were performed on a Biacore X100
instrument (GE Healthcare, Pittsburgh, PA) and evaluated with Biacore
X100 evaluation software (version 1.0). His-tagged AgrAC-C199S was im-
mobilized at 10 g/ml in PBS on a nitrilotriacetic acid (NTA) biosensor
with the NTA reagent kit (GE Healthcare). For binding studies, OHM
(analyte) was dissolved in running buffer (PBS, 5% DMSO [pH 9]) and
applied at a flow rate of 30 l/min with a 180-s contact time and 300-s
dissociation time. The data were fit to a 1:1 binding model after the sub-
traction of blank injections and the removal of injection spikes from the
sensorgrams. NTA biosensor chips were regenerated with the following
sequence: two 60-s washes with 350 mM EDTA, a 60-s wash with PBS, and
a 60-s wash with 500 mM imidazole, followed by a final 60-s wash with
PBS. The analyses were performed at 25°C.
Mouse model of skin and soft tissue infection. The mouse model of
skin and soft tissue infection was previously described and was imple-
mented with minor modifications (42). Early exponential-phase S. aureus
strain LAC was diluted into USP-grade saline (Braun, Irvine, CA) to de-
liver 5  107 to 7  107 CFU per mouse. Aliquots of OHM were diluted in
0.5% hydroxypropylmethylcellulose (HPMC) (pH 11) to deliver 0.2
mg/kg per mouse (5 g). The mice were anesthetized with 3% isoflu-
rane at 3 liters/min. The bacteria and OHM were mixed 1:1 immediately
before subcutaneous injection into the right flank, at a total volume of 50
l. The mice were weighed prior to infection and every day postinfection.
Additionally, the injection sites were photographed daily to determine the
abscess and ulcer areas with ImageJ analysis (43). On day three or day
seven postinfection, each mouse was euthanized by CO2 asphyxiation,
and a 2.25-cm2 section of skin surrounding the abscess was excised. The
tissue was mechanically homogenized and serially plated on sheep blood
agar to determine the bacterial burden. The tissue homogenates were
stored at 80°C until they were rapidly defrosted at 37°C for cytokine
analysis. On day 3 postinfection, the homogenate was centrifuged at
12,500  g for 10 min and the clarified supernatant analyzed with a cus-
tom-designed multiplex assay (Merck KGaA, Darmstadt, Germany) using
a BioPlex 200 with BioPlex Manager software (Bio-Rad, Hercules, CA).
The abscess tissues collected for hematoxylin and eosin (H&E) staining
were fixed overnight in 10% formalin and embedded in paraffin. Five-
micrometer sections were then stained with H&E and imaged using an
Olympus IX70 microscope (Olympus, Center Valley, PA).
Alpha-hemolysin quantification. For the detection of alpha-hemoly-
sin (Hla) in abscess tissue homogenates by Western blot assay, clarified
homogenates were rapidly thawed and an aliquot electrophoresed on a
16% Tris-glycine SDS-PAGE gel (Life Technologies, Grand Island, NY)
before transfer to a polyvinylidene fluoride membrane. The membranes
were blocked for 1 h at RT, using TBST (20 mM Tris [pH 7.5], 150 mM
NaCl, 0.1% Tween 20) with 5% nonfat dry milk. Hla was detected using
anti-Hla antibody (ab15948; Abcam, Cambridge, MA) at a 1:1,000 dilu-
tion and alkaline phosphatase-conjugated secondary antibody. The im-
munoreactive bands were developed with nitroblue tetrazolium (NBT)/
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) (Thermo Scientific) and
intensity measured using a FluorChem R system and the AlphaView soft-
ware (ProteinSimple). Relative intensity was calculated as the measured
intensity divided by the total protein concentration based on absorbance
at 280 nm.
Mouse macrophage killing of S. aureus. Murine macrophage cells
(RAW 264.7) were maintained at 37°C in 5% CO2 in high-glucose Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES, with 100 U/ml
penicillin and 100 g/ml streptomycin. Twenty-four hours prior to the
experiments, the RAW cells were washed with PBS and the medium re-
placed with DMEM, as described above but with 2% FBS without antibi-
otics. Early exponential-phase LAC or LAC
agr was cultured in 3 ml of
TSB at 2  107 CFU/ml at 37°C, with aeration for 5 h, with 50 nM exog-
enous AIP1 (Biopeptide Co.) and 5 g/ml OHM or DMSO (vehicle). The
bacteria were centrifuged, washed in PBS, sonicated, and suspended at
1  108 to 2  108 in DMEM but with 1% FBS without antibiotics. The
bacteria were opsonized overnight at 4°C with rabbit anti-S. aureus IgG at
100 g/ml (catalog no. YVS6881; Accurate Chemical & Scientific Co.,
Westbury, NY). The RAW cells were washed with PBS and suspended at
2  107 cells/ml in DMEM with 1% FBS without antibiotics and com-
bined with opsonized bacteria at a multiplicity of infection (MOI) of 1:1.
The cells were centrifuged at 500  g for 3 min to initiate contact and
incubated at 37°C in 5% CO2 for 1 h to allow phagocytosis. Lysostaphin
(catalog no. L-0761; Sigma-Aldrich) was added at 2 g/ml for 15 min to
kill extracellular bacteria and then removed by centrifugation and replace-
ment with fresh medium. Half of the samples were immediately processed
for CFU determination, and the other half were incubated for an addi-
tional 4 h before CFU enumeration. Intracellular bacteria were enumer-
ated by preliminary dilution into PBS– 0.1% Triton X-100, followed by
sonication and plating onto blood agar.
Human PMN assays. PMNs were purified from normal healthy ve-
nous blood, as described by Nauseef (44). The purified PMNs were sus-
pended in HBSS without divalent cations at 3  107 cells/ml and kept on
ice until use.
PMN phagosomal killing of S. aureus was conducted as previously
described, with the following alterations (45). Prior to opsonization, early
exponential-phase LAC or LAC
agr was cultured in 3 ml of TSB at 2 
107 CFU/ml at 37°C, with aeration for 5 h, with 50 nM exogenous AIP-I
(Biopeptide Co.) and 5 g/ml OHM or DMSO (vehicle). The bacteria
were centrifuged, washed in PBS, and opsonized at 5  106 CFU/ml in
HBSS, with divalent cations supplemented with 20 mM HEPES, 1% hu-
man serum albumin (HSA), and 10% pooled human serum. Following a
20-min incubation with tumbling at 37°C, the bacteria were pelleted,
washed in PBS, and resuspended in HBSS with divalent cations supple-
mented with 20 mM HEPES. The PMNs and opsonized bacteria were
combined at an MOI of 1:1 and incubated for 10 min at 37°C. The extra-
cellular bacteria were removed by centrifugation at 500  g for 5 min,
followed by the resuspension of infected PMNs in HBSS with divalent
cations supplemented with 20 mM HEPES and 1% HSA. The infected
PMNs were incubated at 37°C for 120 min, and the aliquots were removed
at 0, 30, 60, and 120 min. The aliquots were diluted into PBS– 0.1% Triton
X-100 to lyse the cells and then serially diluted and plated on blood agar
for CFU enumeration.
The lysis of PMNs by the S. aureus supernatant was conducted as
previously described, with minor modifications (25). Briefly, LAC was
cultured in 3 ml of TSB for 5 h with 5 g/ml OHM or vehicle, centrifuged,
and the supernatants were filtered through a 0.2-m HT Tuffryn mem-
brane (Pall). The supernatants were stored at 80°C and thawed on ice
prior to use. The PMNs were washed with PBS and resuspended in RPMI
supplemented with 10 mM HEPES and 1% HSA. PMNs at a density of 3 
106 cells/ml in 100 l were added to 100 l of RPMI, RPMI with 10% TSB
(vol/vol), or RPMI with 10% S. aureus supernatant prepared as described
above. The PMNs were incubated at 37°C and 5% CO2 for 2 h. Following
incubation, the supernatants were collected by centrifugation at 3,000  g
for 5 min and assessed for lactate dehydrogenase (LDH) release, according
to the manufacturer’s specifications (CytoTox 96 nonradioactive cytotox-
icity assay; Promega Co., Madison, WI). Triton X-100 was added at a final
concentration of 0.1% (vol/vol) as a 100% lysis control, while cell-free
RPMI with 5% TSB served as a blank. The data are normalized to 100%
lysis control.
Statistical analysis. Statistical evaluations were performed using
GraphPad Prism version 5.04. The in vitro data were analyzed by the
two-tailed Student’s t test, and the in vivo data were analyzed by the Mann-
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Whitney U test for nonparametrics. The results were considered signifi-
cantly different at a P value of 0.05.
RESULTS
-Hydroxyemodin is a universal inhibitor of S. aureus quorum
sensing. Our original report focused on OHM inhibition of QS
using an S. aureus strain derived from the USA300 agr-I isolate
LAC (27). However, isolates from all four agr alleles contribute to
disease in humans. Therefore, to be of maximum utility, a QS
inhibitor must antagonize QS by all four agr alleles. To address
this, we assessed the ability of OHM to inhibit quorum sensing by
isolates of all four agr types using reporter strains expressing yel-
low fluorescent protein (YFP) under the control of the agr::P3
promoter. OHM inhibited QS by all four agr types at concentra-
tions that do not impact bacterial growth (Fig. 2A). As expected
based on the inhibition of agr::P3 promoter activation, OHM de-
creased the transcription of the agr effector RNAIII and agr-regu-
lated virulence factors, including phenol-soluble modulin alpha
(psm	) and alpha-hemolysin (hla) (see Fig. S2A in the supple-
mental material). OHM also inhibited the production of Hla, as
demonstrated by the red blood cell lysis assay (see Fig. S2B in the
supplemental material). Importantly, at concentrations required
for agr inhibition, OHM was nontoxic to human alveolar
(A549), kidney (HEK293), and hepatocyte cell lines (Fig. 2B).
Therefore, these data demonstrate that at concentrations that
are noncytotoxic to eukaryotic cells, OHM is a universal inhib-
itor of S. aureus QS.
-Hydroxyemodin antagonizes AgrA function. The ability of
OHM to antagonize QS by all S. aureus agr alleles pointed to a
target that is well conserved in the system. Therefore, we first
focused on AgrC, the receptor histidine kinase activated by AIP
binding. To determine whether OHM disrupted AgrC activation,
we tested OHM for the inhibition of agr-mediated Hla expression
determined by the lysis of rabbit RBCs, using an agr-I isolate ex-
pressing constitutively active AgrC (R238H [33]). Whereas the
addition of inhibitory AIP (AIP2) reduced Hla expression by S.
aureus expressing wild-type (WT) but not constitutively active
AgrC, OHM inhibited Hla expression by both isolates (Fig. 3A).
These results support a mechanism of action whereby OHM in-
tracellularly inhibits agr signaling, downstream of AgrC activa-
tion.
The response regulator AgrA functions downstream of AgrC,
and we and others have shown that small molecules that target
AgrA disrupt QS (25, 40). Therefore, to further address the mech-
anism of action of OHM, we evaluated potential OHM binding
sites on the crystal structure of the C-terminal AgrA DNA binding
domain (AgrAC) (39, 40). The most favorable binding site for
OHM was near the AgrAC-DNA interface (Fig. 3B). Docking stud-
ies positioned OHM in a pocket between the side chains of H200
and Y229, with Y229 recently identified as a major contributor to
maximal AgrA activity (46), and three residues, R218, S231, and
V232, which make direct interactions with bound DNA in the
AgrA-DNA crystal structure (38). Given this, together with obser-
vations that OHM is within hydrogen bonding distance of R218
and that naturally occurring mutations at R218 result in agr-neg-
ative phenotypes (47), we predicted that OHM would inhibit
AgrA binding to promoter DNA. To test this, we expressed AgrAC
and measured binding to fluorescently labeled duplex agr pro-
moter DNA encompassing the high-affinity binding site located in
the agr P2 and P3 promoters (P2-FAM). As expected, OHM dem-
onstrated a dose-dependent inhibition of AgrAC binding to agr
promoter DNA by an electrophoretic mobility shift assay (EMSA)
(see Fig. S3A in the supplemental material). In addition, we devel-
oped a bead-based assay to measure transcription factor binding
to target DNA using flow cytometry. Biotinylated AgrAC was im-
mobilized on streptavidin beads (SA beads), and the binding to
promoter DNA was measured by flow cytometry. As expected,
OHM again demonstrated a dose-dependent inhibition of AgrAC
binding to agr promoter DNA (Fig. 3C). Furthermore, OHM
bound directly to immobilized AgrAC, as shown by surface plas-
mon resonance (SPR) analysis (Fig. 3D). Finally, because the
amino acid sequence in the predicted OHM binding site of S.
aureus AgrA is highly conserved with that of S. epidermidis AgrA,
we postulated that OHM would also inhibit agr signaling by S.
epidermidis. As expected, OHM significantly inhibited agr activa-
tion by agr-I S. epidermidis (see Fig. S3B in the supplemental ma-
terial). Together, these data strongly suggest that OHM inhibits
agr signaling by binding to AgrA and blocking AgrA function.
To begin to address the specificity of OHM for agr inhibition,
FIG 2 -Hydroxyemodin inhibits S. aureus quorum sensing by all four agr
alleles. (A) Effect of OHM on agr::P3 promoter activation (open symbols) and
cell growth (closed symbols), measured by flow cytometry and OD600, respec-
tively, for agr-I (red circles), agr-II (blue squares), agr-III (green triangles), and
agr-IV isolates (black diamonds). (B) Percent cell viability of A549 (blue cir-
cles), HEK293 (red squares), and HepG2 (green triangles) cells measured by
XTT assay after 24 h of incubation with the indicated concentrations of OHM.
The dashed vertical lines indicate the concentration used for the in vitro assays.
Data are shown as means  SEM. The experiments were performed in tripli-
cate or quadruplicate.
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we used qPCR to evaluate the effects of OHM on transcription of
a series of agr- and non-agr-regulated genes involved in virulence,
the stress response, metabolism, and drug efflux and resistance
(14, 25, 48, 49) (Table 1; see also Fig. S4 in the supplemental
material). With respect to virulence genes, OHM treatment re-
sulted in a slight yet nonsignificant increase in the transcription of
spa, which encodes protein A and is negatively regulated by agr
(14). In contrast, the expression of the enterotoxin gene set7 de-
creased with OHM in LAC but not LAC
agr, and OHM had no
effect on the expression of the saeR component of the SaeRS vir-
ulence regulator. Likewise, the transcription of genes involved in
the stress response (asp23, crtM, and clpB) was not altered by
OHM, suggesting that OHM does not induce a general stress re-
sponse in LAC under the conditions tested (50–54). Among the
metabolism genes examined, OHM had no significant effect on
the transcription of the genes involved in electron transport (atpG
and sdhA). However, OHM treatment significantly decreased the
transcription of murQ, an N-acetylmuramic acid 6-phosphate
lyase, in both LAC and LAC
agr. Although this protein, which is
involved in cell wall recycling, is dispensable for growth in E. coli
(55–57), its contribution to the growth of Gram-positive patho-
gens is less clear. However, the absence of bactericidal or bacterio-
static effects with OHM treatment suggests that MurQ is not re-
quired for growth under the conditions tested. In addition, OHM
treatment did not increase the transcription of genes examined for
their potential to contribute to drug efflux or resistance. There-
fore, although there are some non-agr effects, these results suggest
that OHM is not a general inhibitor of transcription or energetics,
nor is it a general inducer of drug efflux. Furthermore, together
with the above demonstrations of (i) OHM-mediated agr inhibi-
tion in a whole-cell assay, (ii) OHM-mediated inhibition of AgrAC
binding to agr promoter DNA by both EMSA and bead-based
assay, and (iii) the direct binding of OHM to AgrAC shown by
SPR (Fig. 2 and 3), these results are consistent with a mechanism
FIG 3 -Hydroxyemodin inhibits AgrA binding to promoter DNA. (A) Effect of OHM on agr::P3 promoter activation assessed by rabbit red blood cell lysis for
AgrC-WT isolate AH3469 and AgrC-R238H isolate AH3470. The data are the mean relative lysis  standard error of the mean (SEM) compared to the vehicle
control. The experiments were performed in triplicate. ns, not significant. (B) Space-fill model of AgrAC showing potential binding site for OHM. Inset,
ball-and-stick representation of OHM binding site. (C) Flow cytometric bead-based assay to determine the effect of OHM on the binding of P2-FAM to
biotinylated AgrAC immobilized on streptavidin beads (SA beads). Unlabeled P2 binding to immobilized AgrAC in competition with P2-FAM was included as
a specificity control. The data are the mean  SEM (n  3). (D) Surface plasmon resonance analysis of OHM binding to 6-His-tagged AgrAC-C199S immobilized
on a nitrilotriacetic acid biosensor. The 50% inhibitory concentration (IC50) was calculated as described in Materials and Methods. Kd, dissociation constant. *,
P  0.05; **, P  0.01; ***, P  0.001; ****, P  0.0001 by Student’s t test.
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whereby OHM predominantly functions as an inhibitor of agr
activation.
-Hydroxyemodin attenuates S. aureus SSTI. Invasive S. au-
reus SSTIs require agr-regulated virulence factors (14, 19, 58–60).
Therefore, we assessed the efficacy of OHM in an established
mouse model of S. aureus SSTI (42). Over the course of a three-
day infection with the USA300 isolate LAC, a single 5-g dose of
OHM administered at the time of infection significantly inhibited
abscess (Fig. 4A and B) and ulcer (dermonecrosis) formation (Fig.
4A and C), as well as morbidity at day one postinfection (assessed
by weight loss) compared to that of the vehicle-treated controls
(Fig. 4D). In contrast, no differences were observed between the
OHM and vehicle-treated mice infected with LAC
agr (Fig. 4A
and data not shown), demonstrating the specificity of OHM for
disrupting agr signaling without directly impacting the host. Im-
portantly, the single OHM treatment reduced the day three and
day seven postinfection bacterial burden at the site of infection in
LAC-infected (Fig. 4E) but not 
agr-infected mice (Fig. 4F), sug-
gesting that mice were better able to combat the infection in the
absence of agr signaling.
We predicted that if OHM treatment supported host-mediated
clearance by disrupting agr signaling, OHM-treated LAC, but not
LAC
agr, would be more readily killed by innate immune cells in
vitro compared to in the vehicle-treated controls. As predicted,
OHM treatment of LAC, but not LAC
agr, resulted in signifi-
cantly increased intracellular killing by both mouse macrophages
(Fig. 5A) and human PMNs (Fig. 5B) compared to that in the
vehicle-treated controls. This increased killing was not a result of
OHM-mediated effects on opsonophagocytosis, as the total num-
ber of bacteria phagocytosed (see Fig. S5 in the supplemental ma-
terial) and the percentage of bacteria phagocytosed relative to the
total inoculum (data not shown) were equivalent, regardless of
whether the bacteria were pretreated with vehicle or OHM. Fur-
thermore, OHM treatment of LAC but not LAC
agr protected
human PMNs from killing by secreted agr-regulated virulence
factors. PMNs showed significantly increased survival in the pres-
ence of supernatant from OHM- versus vehicle-treated LAC (Fig.
5C). Together, these results demonstrate that OHM supports the
host-mediated clearance of S. aureus by inhibiting agr-mediated
virulence.
-Hydroxyemodin limits inflammation mediated by S. au-
reus QS. S. aureus uses a variety of virulence factors, many of
which are regulated by the agr system, to evade host clearance
mechanisms. These virulence factors cause tissue damage and
inflammation and facilitate invasive infection (61–65). There-
fore, we postulated that the reduction in bacterial burden in the
LAC-infected, OHM-treated mice would be associated with
reduced tissue damage and reduced local inflammatory cyto-
kine production compared to the vehicle-treated controls. His-
tological analysis of day three postinfection skin sections
confirmed the overall reduction in abscess formation and ul-
ceration in OHM-treated mice (Fig. 6A). Additionally, skin
sections from the vehicle-treated mice displayed a disorganized
architecture at both the epithelium-to-necrosis transition (Fig.
6A, left inset) and the abscess periphery (right inset) compared
to sections from OHM-treated mice. Also as predicted, OHM
treatment resulted in a local cytokine profile matching that of
LAC
agr-infected mice on day three postinfection (Fig. 6B),
with significant reductions in interleukin-1 (IL-1), tumor
necrosis factor alpha (TNF-	), and IL-6, but not the anti-in-
flammatory cytokine IL-10, compared to the vehicle-treated
controls. LAC-infected mice treated with OHM also showed
reduced transcription of il-1, tnf	, and il-6 at 24 h postinfec-
tion compared to the levels in the vehicle-treated mice (Fig.
6C). Finally, the activation of the NLRP3 inflammasome and
the subsequent release of IL-1 is induced by pore formation in
the host cell membranes by Hla (66–68), and the passive trans-
fer of Hla-neutralizing antibodies is sufficient to limit the se-
cretion of IL-1 (69). Therefore, we predicted that OHM treat-
ment would be associated with reduced Hla expression and
TABLE 1 Transcriptional analysis of the agr specificity of OHM
Focus Gene agr regulation/association
Fold change in gene expression (vehicle/OHM
treatment)a
LAC P value 
agrb P value
Virulence spa (SAUSA300_0113) Neg 2 ND
set7 (SAUSA300_0396) NAc 2.84 0.0019 2
saeR (SAUSA300_0691) Pos 2 ND
Stress response asp23 (SAUSA300_2142) NA 2 ND
crtM (SAUSA300_2499) NA 2 ND
clpB (SAUSA300_0877) NA 2 ND
Metabolism atpG (SAUSA300_2059) NA 2 ND
murQ (SAUSA300_0193) Pos 4.99 0.0001 8.551 0.0001
sdhA (SAUSA300_1047) NA 2 ND
Efflux/antibiotic resistance norA (SAUSA300_0680) NA 2 ND
mdrA (SAUSA300_2299) NA 2 ND
NaMDR gened
(SAUSA300_0335)
NA 3.23 0.0015 2.26 0.0076
a Values are shown if 2-fold.
b Assay performed with 
agr strain if 2-fold difference with OHM treatment of LAC. ND, not done.
c NA, not applicable.
d NaMDR, Na-driven multidrug efflux pump.
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nlrp3 transcription at the site of infection. As expected, the
OHM-treated mice showed decreased local Hla expression and
decreased transcription of nlrp3 compared to the vehicle-
treated controls (Fig. 6D and E). Together, these data demon-
strate that OHM inhibition of agr signaling limits host tissue
damage and inflammation during S. aureus SSTI.
DISCUSSION
Recently, the National Institutes of Allergy and Infectious Diseases
reported on the current status and future directions for its anti-
bacterial resistance program (70). Two of the strategic approaches
highlighted were (i) antivirulence strategies to disarm bacteria to
reduce pathogenesis and (ii) approaches to harness the host im-
mune system to better combat infections. Here, we report that
OHM, a natural product isolated from the fungus P. restrictum
FIG 4 -Hydroxyemodin limits abscess formation and dermonecrosis and
promotes bacterial clearance in a mouse model of S. aureus SSTI. SKH1 mice
were subcutaneously injected with 5  107 to 7  107 CFU of LAC or 
agr
along with OHM (0.2 mg/kg) or vehicle control. (A) Representative images of
abscesses and ulcers on day three postinfection (D3) (scale bar  5 mm). Day
3 postinfection abscess (B), ulcer area (C), and weight loss of LAC-infected
mice. (E) Day 3 and day 7 postinfection bacterial burden at the site of infection.
The data shown are the mean  SEM (LAC, day 3, n  12 to 16 mice per group;
day 7, n  5 mice per group). (F) 
agr day 3 bacterial burden at the site of
infection. n  6 mice per group. ns, not significant. *, P  0.05; **, P  0.01 by
Mann-Whitney U test.
FIG 5 -Hydroxyemodin supports immune cell killing of agr S. aureus. (A)
Mouse macrophage (RAW 264.7) intracellular killing of bacteria pretreated
with OHM or vehicle control. The data are shown as the mean  SEM nor-
malized to 100% after 1 h of incubation at an MOI of 1:1. n  6 from two
independent experiments performed in triplicate. (B) Human polymorpho-
nuclear leukocyte (PMN) intracellular killing of bacteria pretreated with OHM
or vehicle control. The data are the mean  SEM presented as the percent
survival (top) and log CFU reduction (bottom) compared to time zero. (C)
Supernatant lysis of human PMNs, assessed by LDH release, after 2 h of incu-
bation with sterile supernatant from overnight cultures grown in the presence
of OHM or vehicle control. The data are the mean  SEM, presented as
percent PMN viability compared to 100% lysis by Triton X-100. (B and C)
Experiments were performed in triplicate with PMNs from two separate do-
nors. A representative donor experiment is shown. ns, not significant. **, P 
0.01; ***, P  0.001; ****, P  0.0001 by Student’s t test.
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(27), addresses both goals by directly inhibiting S. aureus QS-
dependent virulence while indirectly bolstering the host immune
response against S. aureus infection. In a mouse model of S. aureus
SSTI, OHM significantly decreases abscess and ulcer formation
and promotes bacterial clearance. Importantly, OHM treatment
reduces tissue damage and limits local proinflammatory cytokine
production to levels seen in mice infected with the agr deletion
mutant. Furthermore, OHM treatment enhances immune cell-
mediated killing of S. aureus in an agr-dependent manner. There-
fore, these data demonstrate that antivirulence strategies can limit
disease by disarming the bacteria while concurrently reducing in-
flammation and promoting host innate defense. In addition, this
is the first polyhydroxyanthraquinone described with in vivo effi-
cacy against MRSA infection, adding to the expanse of natural
products with the potential to promote human health and ad-
vance antibiotic stewardship.
Numerous reviews have addressed the potential role of anti-
virulence strategies, including the disruption of QS, in combating
the antimicrobial resistance crisis (4, 6, 7, 71–73). We chose to
focus on the disruption of agr QS as an antivirulence approach to
S. aureus SSTIs due to their predominance in S. aureus disease
manifestations, as well as the established contribution of agr in
facilitating these infections (11–14, 19). For example, agr deletion
mutants (
agr) are less pathogenic and more readily cleared dur-
ing SSTIs than are wild-type strains (14, 19), and host innate ef-
fectors that disrupt agr signaling limit disease in skin infection
models (20–22). Importantly, the sterile supernatant from agr
but not from agr-null S. aureus strains is sufficient to cause skin
lesions similar to those in an active infection, definitively demon-
strating the role of agr-regulated secreted virulence factors in skin
pathogenesis (58). Here, we used OHM in a prophylactic admin-
istration model, similar to that previously reported for the admin-
istration of competing AIP or the passive transfer of monoclonal
antibodies targeting AIP4 (24, 58), to demonstrate that small-
molecule-mediated disruption of agr signaling in vivo results in an
“agr-null-like” host inflammatory profile.
The disruption of agr signaling during SSTIs results in reduced
bacterial burden at various time points postinfection (19, 25, 58,
60), suggesting that host-mediated bacterial clearance is more ef-
fective in the absence of QS. In support of this, we have shown here
and elsewhere (25) that agr inhibitors enhance some mechanisms
of innate immune bacterial clearance against agr S. aureus. The
increased bacterial clearance likely results from inhibiting the ex-
pression of the agr-regulated secretome, which includes virulence
factors that target host immune cells. Among these, the phenol-
soluble modulins (PSMs) and Hla, in particular, contribute to
abscess formation, dermonecrosis, and bacterial burden during
SSTIs (59, 60, 74, 75). These toxins target a variety of cell types to
suppress both innate and adaptive immunity (76). For example, S.
aureus utilizes Hla to survive inside neutrophils and macrophages
(45, 77–80) and to induce programmed cell death in T cells, B
cells, and monocytes (81). In addition, Hla activates the NLRP3
inflammasome in a variety of cells, resulting in the release of the
inflammatory cytokine IL-1 (67, 68, 82). Although neutrophils
and IL-1 are needed for the ultimate clearance of S. aureus SSTI
(83, 84), limiting inflammation caused by bacterial toxins clearly
benefits the host.
Our molecular modeling studies positioned OHM near R218
of S. aureus AgrA. This residue, which is strictly conserved across
multiple staphylococcal species (46), is required for agr function
and contributes to AgrA binding to agr promoter DNA (38, 47).
Although the potential exists for OHM to drive selection for an
FIG 6 -Hydroxyemodin limits pathology and expression of inflammatory cytokines during S. aureus SSTI. (A) Top, representative hematoxylin and eosin
micrographs of 5-m sagittal sections of day three post-LAC infection abscess tissue. The abscess area is demarcated by a fine dashed line, while the ulcer surface
length is marked by the thick dash line. Bottom, magnification of the transition from normal epithelium to necrotic tissue (left) and organization of the abscess
tissue (right). (B) Multiplex analysis of cytokines present in the abscess tissue on day three postinfection with LAC or 
agr. (C and E) Quantification of il-1, tnf	,
il-6 (C), and nlrp3 (E) relative to hprt in abscess tissue at 24 h post-LAC infection. (D) Western blot analysis and quantification of Hla at the site of infection (day
3) in OHM- versus vehicle-treated mice (n  4 mice/group). The data are the mean  SEM from infection data, as described in the legend to Fig. 4. RQ, relative
quantification; *, P  0.05; **, P  0.01; ***, P  0.001 by Student’s t test.
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alternative amino acid at residue 218, any such mutation would
likely result in agr dysfunction. The selection for QS-deficient iso-
lates is unlikely to be of significant benefit to the pathogen, as these
isolates are severely attenuated, more readily cleared by host de-
fenses, and less effective at initiating infection (19, 37, 60). How-
ever, while the residues directly involved in OHM binding have yet
to be definitively demonstrated, the question of whether OHM
can select for mutation of other residues in the predicted binding
site that would prevent OHM function while retaining agr activity
will require empirical determination.
Along with inhibiting S. aureus agr activation, OHM likewise
inhibits agr signaling by S. epidermidis, an important member of
the skin microbiome and also an opportunistic pathogen (85). S.
epidermidis agr regulation drives the mechanisms of resistance to
host innate defense (86), suggesting that OHM or related ana-
logues might prove efficacious against S. epidermidis infections.
However, in its role as a commensal, S. epidermidis appears to
benefit the host by such means as competing with S. aureus for
colonization and contributing to overall skin immunity (87–89).
Additionally, AIP1 produced by S. epidermidis is cross-inhibitory
to S. aureus agr types I to III in vitro (85, 90, 91). Therefore, it is
unclear whether OHM-mediated perturbation of S. epidermidis
QS, during treatment for S. aureus SSTI, might result in unwar-
ranted complications, such as increased host-mediated clearance
of S. epidermidis and/or the loss of potentially beneficial cross-
inhibitory AIP. To address these possibilities, it will be important
to experimentally determine the in vivo implications of disrupting
QS in an S. epidermidis-colonized host on subsequent S. aureus
skin infection.
As is the case with existing antimicrobials, QS inhibitors (QSIs)
may not be a one-size-fits-all solution. Although SSTIs comprise
the vast majority of S. aureus infections, this pathogen causes a
variety of disease manifestations, including pneumonia, osteomy-
elitis, endocarditis, and bloodstream infections (BSI). This raises
the question of whether the use of QSIs will be universally bene-
ficial. The contribution of agr to S. aureus pathogenesis has largely
been demonstrated in models of SSTIs and pneumonia (14, 19, 24,
92). In contrast, agr dysfunction has been associated with persis-
tent bacteremia in hospitalized patients (83, 84), suggesting that
QSIs would be best utilized to prevent S. aureus invasion prior to
BSI. Likewise, the disruption of agr is associated with biofilm for-
mation in vitro (85), potentially limiting the utility of QSIs for the
treatment of infections involving implanted devices, as well as
osteomyelitis and endocarditis. Whether OHM and other QSIs
would contribute to staphylococcal biofilm formation in vivo will
require investigation in appropriate animal models of infection.
Overall, however, QSIs might be a critical part of the developing
arsenal for combating antibiotic resistance either alone, as ad-
juncts to existing antibiotics, or along with potential vaccines or
other approaches to augment host defense.
A substantial portion of the compounds used to fight infec-
tions have their origins in natural products (26). Despite clearly
representing a wealth of bioactive molecules, natural products
have received limited attention with respect to identifying specific
inhibitors of S. aureus QS that are not bactericidal. To date, other
natural products identified as agr inhibitors include (i) 	-cyper-
one from the nut grass plant Cyperus rotundus (93), (ii) the fungal
metabolite ambuic acid (94), and extracts from (iii) the goldenseal
plant Hydrastis canadensis (95) and (iv) three Italian medicinal
plants, Ballota nigra, Castanea sativa, and Sambucus ebulus (96).
Among these, OHM is the first to demonstrate in vivo efficacy
against S. aureus QS. Therefore, we predict that targeted testing of
structurally diverse natural products will continue to reveal a
broad range of antivirulence molecules with the potential to sup-
port innate host defense mechanisms and to positively contribute
to antibiotic stewardship.
ACKNOWLEDGMENTS
This work was supported by NIH grants AI091917 (to P.R.H.) and
AT007052 (to A.R.H.). S.M.D. was supported by the University of New
Mexico Infectious Diseases and Inflammation Training Grant T32-
AI007538. H.A.C. was supported by NIH T32 training grant AI007511.
The isolation and characterization of -hydroxyemodin was supported
initially by a Biotechnology Research Grant (2011-BRG-1206) from the
North Carolina Biotechnology Center (to N.H.O.).
We thank Richard S. Larson and Scott W. Burchiel for the use of
critical equipment.
REFERENCES
1. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and
resistance. N Engl J Med 368:299–302. http://dx.doi.org/10.1056/NEJMp
1215093.
2. Nathan C. 2012. Fresh approaches to anti-infective therapies. Sci Transl
Med 4:140sr142. http://dx.doi.org/10.1126/scitranslmed.3003081.
3. Park B, Liu GY. 2012. Targeting the host-pathogen interface for treat-
ment of Staphylococcus aureus infection. Semin Immunopathol 34:299 –
315. http://dx.doi.org/10.1007/s00281-011-0297-1.
4. Rutherford ST, Bassler BL. 2012. Bacterial quorum sensing: its role in
virulence and possibilities for its control. Cold Spring Harb Perspect Med
2:a012427. http://dx.doi.org/10.1101/cshperspect.a012427.
5. Gray B, Hall P, Gresham H. 2013. Targeting agr- and agr-like quorum
sensing systems for development of common therapeutics to treat multi-
ple Gram-positive bacterial infections. Sensors 13:5130 –5166. http://dx
.doi.org/10.3390/s130405130.
6. Rasko DA, Sperandio V. 2010. Anti-virulence strategies to combat bac-
teria-mediated disease. Nat Rev Drug Discov 9:117–128. http://dx.doi.org
/10.1038/nrd3013.
7. Zhu J, Kaufmann GF. 2013. Quo vadis quorum quenching? Curr Opin
Pharmacol 13:688 – 698. http://dx.doi.org/10.1016/j.coph.2013.07.003.
8. Rampioni G, Leoni L, Williams P. 2014. The art of antibacterial warfare:
deception through interference with quorum sensing-mediated commu-
nication. Bioorg Chem 55:60 – 68. http://dx.doi.org/10.1016/j.bioorg
.2014.04.005.
9. Harraghy N, Kerdudou S, Herrmann M. 2007. Quorum-sensing systems
in staphylococci as therapeutic targets. Anal Bioanal Chem 387:437– 444.
http://dx.doi.org/10.1007/s00216-006-0860-0.
10. Cegelski L, Marshall GR, Eldridge GR, Hultgren SJ. 2008. The biology
and future prospects of antivirulence therapies. Nat Rev Microbiol 6:17–
27. http://dx.doi.org/10.1038/nrmicro1818.
11. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK,
Carey RB, Talan DA, EMERGEncy ID Net Study Group. 2006. Methicillin-
resistant S. aureus infections among patients in the emergency department.
N Engl J Med 355:666 – 674. http://dx.doi.org/10.1056/NEJMoa055356.
12. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339:520 –
532. http://dx.doi.org/10.1056/NEJM199808203390806.
13. Tong SY, Chen LF, Fowler VG. 2012. Colonization, pathogenicity, host
susceptibility, and therapeutics for Staphylococcus aureus: what is the clin-
ical relevance? Semin Immunopathol 34:185–200. http://dx.doi.org/10
.1007/s00281-011-0300-x.
14. Cheung GY, Wang R, Khan BA, Sturdevant DE, Otto M. 2011. Role of
the accessory gene regulator agr in community-associated methicillin-
resistant Staphylococcus aureus pathogenesis. Infect Immun 79:1927–
1935. http://dx.doi.org/10.1128/IAI.00046-11.
15. Novick RP, Geisinger E. 2008. Quorum sensing in staphylococci. Annu
Rev Genet 42:541–564. http://dx.doi.org/10.1146/annurev.genet.42.110
807.091640.
16. Thoendel M, Kavanaugh JS, Flack CE, Horswill AR. 2011. Peptide
signaling in the staphylococci. Chem Rev 111:117–151. http://dx.doi.org
/10.1021/cr100370n.
17. Jacobsson G, Gustafsson E, Andersson R. 2008. Outcome for invasive
Daly et al.
2232 aac.asm.org April 2015 Volume 59 Number 4Antimicrobial Agents and Chemotherapy
 on A


































Staphylococcus aureus infections. Eur J Clin Microbiol Infect Dis 27:839 –
848. http://dx.doi.org/10.1007/s10096-008-0515-5.
18. Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F,
Nesme X, Etienne J, Vandenesch F. 2002. Relationships between Staph-
ylococcus aureus genetic background, virulence factors, agr groups (al-
leles), and human disease. Infect Immun 70:631– 641. http://dx.doi.org
/10.1128/IAI.70.2.631-641.2002.
19. Montgomery CP, Boyle-Vavra S, Daum RS. 2010. Importance of the
global regulators agr and SaeRS in the pathogenesis of CA-MRSA USA300
infection. PLoS One 5:e15177. http://dx.doi.org/10.1371/journal.pone
.0015177.
20. Rothfork JM, Timmins GS, Harris MN, Chen X, Lusis AJ, Otto M,
Cheung AL, Gresham HD. 2004. Inactivation of a bacterial virulence
pheromone by phagocyte-derived oxidants: new role for the NADPH ox-
idase in host defense. Proc Natl Acad Sci U S A 101:13867–13872. http:
//dx.doi.org/10.1073/pnas.0402996101.
21. Hall PR, Elmore BO, Spang CH, Alexander SM, Manifold-Wheeler BC,
Castleman MJ, Daly SM, Peterson MM, Sully EK, Femling JK, Otto M,
Horswill AR, Timmins GS, Gresham HD. 2013. Nox2 modification of
LDL is essential for optimal apolipoprotein B-mediated control of agr type
III Staphylococcus aureus quorum-sensing. PLoS Pathog 9:e1003166. http:
//dx.doi.org/10.1371/journal.ppat.1003166.
22. Nishimura H, Mayama M, Komatsu Y, Kato H, Shimaoka N, Tanaka Y.
1964. Showdomycin, a new antibiotic from a Streptomyces sp. J Antibiot
(Tokyo) 17:148 –155.
23. Schlievert PM, Case LC, Nemeth KA, Davis CC, Sun Y, Qin W, Wang
F, Brosnahan AJ, Mleziva JA, Peterson ML, Jones BE. 2007. Alpha and
beta chains of hemoglobin inhibit production of Staphylococcus aureus
exotoxins. Biochemistry 46:14349 –14358. http://dx.doi.org/10.1021/bi
701202w.
24. Park J, Jagasia R, Kaufmann GF, Mathison JC, Ruiz DI, Moss JA,
Meijler MM, Ulevitch RJ, Janda KD. 2007. Infection control by antibody
disruption of bacterial quorum sensing signaling. Chem Biol 14:1119 –
1127. http://dx.doi.org/10.1016/j.chembiol.2007.08.013.
25. Sully EK, Malachowa N, Elmore BO, Alexander SM, Femling JK, Gray
BM, DeLeo FR, Otto M, Cheung AL, Edwards BS, Sklar LA, Horswill
AR, Hall PR, Gresham HD. 2014. Selective chemical inhibition of agr
quorum sensing in Staphylococcus aureus promotes host defense with
minimal impact on resistance. PLoS Pathog 10:e1004174. http://dx.doi
.org/10.1371/journal.ppat.1004174.
26. Newman DJ, Cragg GM. 2012. Natural products as sources of new drugs
over the 30 years from 1981 to 2010. J Nat Prod 75:311–335. http://dx.doi
.org/10.1021/np200906s.
27. Figueroa M, Jarmusch AK, Raja HA, El-Elimat T, Kavanaugh JS,
Horswill AR, Cooks RG, Cech NB, Oberlies NH. 2014. Polyhydroxyan-
thraquinones as quorum sensing inhibitors from the guttates of Penicil-
lium restrictum and their analysis by desorption electrospray ionization
mass spectrometry. J Nat Prod 77:1351–1358. http://dx.doi.org/10.1021
/np5000704.
28. Malone CL, Boles BR, Lauderdale KJ, Thoendel M, Kavanaugh JS,
Horswill AR. 2009. Fluorescent reporters for Staphylococcus aureus. J Mi-
crobiol Methods 77:251–260. http://dx.doi.org/10.1016/j.mimet.2009.02
.011.
29. Olson ME, Todd DA, Schaeffer CR, Paharik AE, Van Dyke MJ, Buttner
H, Dunman PM, Rohde H, Cech NB, Fey PD, Horswill AR. 2014.
Staphylococcus epidermidis agr quorum-sensing system: signal identifica-
tion, cross talk, and importance in colonization. J Bacteriol 196:3482–
3493. http://dx.doi.org/10.1128/JB.01882-14.
30. Rothfork JM, Dessus-Babus S, Wamel WJV, Cheung AL, Gresham HD.
2003. Fibrinogen depletion attenuates Staphylococcus aureus infection by
preventing density-dependent virulence gene up-regulation. J Immunol
171:5389 –5395. http://dx.doi.org/10.4049/jimmunol.171.10.5389.
31. Bernheimer AW. 1988. Assay of hemolytic toxins. Methods Enzymol
165:213–217. http://dx.doi.org/10.1016/S0076-6879(88)65033-6.
32. Corrigan RM, Foster TJ. 2009. An improved tetracycline-inducible ex-
pression vector for Staphylococcus aureus. Plasmid 61:126 –129. http://dx
.doi.org/10.1016/j.plasmid.2008.10.001.
33. Geisinger E, Muir TW, Novick RP. 2009. agr receptor mutants reveal
distinct modes of inhibition by staphylococcal autoinducing peptides.
Proc Natl Acad Sci U S A 106:1216 –1221. http://dx.doi.org/10.1073/pnas
.0807760106.
34. Fey PD, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ, Bose JL, Bayles
KW. 2013. A genetic resource for rapid and comprehensive phenotype
screening of nonessential Staphylococcus aureus genes. mBio 4(1):e00537–
12. http://dx.doi.org/10.1128/mBio.00537-12.
35. Luong TT, Lee CY. 2007. Improved single-copy integration vectors for
Staphylococcus aureus. J Microbiol Methods 70:186 –190. http://dx.doi.org
/10.1016/j.mimet.2007.04.007.
36. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger
TH, Currens MJ, Seniff D, Boyd MR. 1988. Evaluation of a soluble
tetrazolium formazan assay for cell-growth and drug sensitivity in culture
using human and other tumor-cell lines. Cancer Res 48:4827– 4833.
37. Sun F, Liang H, Kong X, Xie S, Cho H, Deng X, Ji Q, Zhang H, Alvarez
S, Hicks LM, Bae T, Luo C, Jiang H, He C. 2012. Quorum-sensing agr
mediates bacterial oxidation response via an intramolecular disulfide re-
dox switch in the response regulator AgrA. Proc Natl Acad Sci U S A
109:9095–9100. http://dx.doi.org/10.1073/pnas.1200603109.
38. Sidote DJ, Barbieri CM, Wu T, Stock AM. 2008. Structure of the Staph-
ylococcus aureus AgrA LytTR domain bound to DNA reveals a beta fold
with an unusual mode of binding. Structure 16:727–735. http://dx.doi.org
/10.1016/j.str.2008.02.011.
39. Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and
accuracy of docking with a new scoring function, efficient optimization,
and multithreading. J Comput Chem 31:455– 461. http://dx.doi.org/10
.1002/jcc.21334.
40. Leonard PG, Bezar IF, Sidote DJ, Stock AM. 2012. Identification of a
hydrophobic cleft in the LytTR domain of AgrA as a locus for small mol-
ecule interactions that inhibit DNA binding. Biochemistry 51:10035–
10043. http://dx.doi.org/10.1021/bi3011785.
41. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H,
Shindyalov IN, Bourne PE. 2000. The Protein Data Bank. Nucleic Acids
Res 28:235–242. http://dx.doi.org/10.1093/nar/28.1.235.
42. Malachowa N, Kobayashi SD, Braughton KR, DeLeo FR. 2013. Mouse
model of Staphylococcus aureus skin infection. Methods Mol Biol 1031:
109 –116. http://dx.doi.org/10.1007/978-1-62703-481-4_14.
43. Schneider CA, Rasband WS, Eliceiri KW. 2012. NIH Image to ImageJ: 25
years of image analysis. Nat Methods 9:671– 675. http://dx.doi.org/10
.1038/nmeth.2089.
44. Nauseef WM. 2014. Isolation of human neutrophils from venous blood.
Methods Mol Biol 1124:13–18. http://dx.doi.org/10.1007/978-1-62703
-845-4_2.
45. Pang YY, Schwartz J, Thoendel M, Ackermann LW, Horswill AR,
Nauseef WM. 2010. agr-dependent interactions of Staphylococcus aureus
USA300 with human polymorphonuclear neutrophils. J Innate Immun
2:546 –559. http://dx.doi.org/10.1159/000319855.
46. Nicod SS, Weinzierl RO, Burchell L, Escalera-Maurer A, James EH,
Wigneshweraraj S. 2014. Systematic mutational analysis of the LytTR
DNA binding domain of Staphylococcus aureus virulence gene transcrip-
tion factor AgrA. Nucleic Acids Res 42:12523–12536. http://dx.doi.org/10
.1093/nar/gku1015.
47. Shopsin B, Eaton C, Wasserman GA, Mathema B, Adhikari RP, Agolory
S, Altman DR, Holzman RS, Kreiswirth BN, Novick RP. 2010. Muta-
tions in agr do not persist in natural populations of methicillin-resistant
Staphylococcus aureus. J Infect Dis 202:1593–1599. http://dx.doi.org/10
.1086/656915.
48. Dunman PM, Murphy E, Haney S, Palacios D, Tucker-Kellogg G, Wu
S, Brown EL, Zagursky RJ, Shlaes D, Projan SJ. 2001. Transcription
profiling-based identification of Staphylococcus aureus genes regulated by
the agr and/or sarA loci. J Bacteriol 183:7341–7353. http://dx.doi.org/10
.1128/JB.183.24.7341-7353.2001.
49. Nagarajan V, Smeltzer MS, Elasri MO. 2009. Genome-scale transcrip-
tional profiling in Staphylococcus aureus: bringing order out of chaos.
FEMS Microbiol Lett 295:204 –210. http://dx.doi.org/10.1111/j.1574
-6968.2009.01595.x.
50. Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN,
Romesberg FE. 2007. Complete and SOS-mediated response of Staphy-
lococcus aureus to the antibiotic ciprofloxacin. J Bacteriol 189:531–539.
http://dx.doi.org/10.1128/JB.01464-06.
51. Baker J, Sitthisak S, Sengupta M, Johnson M, Jayaswal RK, Morrissey
JA. 2010. Copper stress induces a global stress response in Staphylococcus
aureus and represses sae and agr expression and biofilm formation. Appl
Environ Microbiol 76:150 –160. http://dx.doi.org/10.1128/AEM.02268
-09.
52. Dengler V, Meier PS, Heusser R, Berger-Bachi B, McCallum N. 2011.
Induction kinetics of the Staphylococcus aureus cell wall stress stimulon in
Natural Product Limits of S. aureus Virulence
April 2015 Volume 59 Number 4 aac.asm.org 2233Antimicrobial Agents and Chemotherapy
 on A


































response to different cell wall active antibiotics. BMC Microbiol 11:16.
http://dx.doi.org/10.1186/1471-2180-11-16.
53. Reiss S, Pane-Farre J, Fuchs S, Francois P, Liebeke M, Schrenzel J,
Lindequist U, Lalk M, Wolz C, Hecker M, Engelmann S. 2012. Global
analysis of the Staphylococcus aureus response to mupirocin. Antimicrob
Agents Chemother 56:787– 804. http://dx.doi.org/10.1128/AAC.05363
-11.
54. Song Y, Lunde CS, Benton BM, Wilkinson BJ. 2012. Further insights
into the mode of action of the lipoglycopeptide telavancin through global
gene expression studies. Antimicrob Agents Chemother 56:3157–3164.
http://dx.doi.org/10.1128/AAC.05403-11.
55. Reith J, Mayer C. 2011. Peptidoglycan turnover and recycling in Gram-
positive bacteria. Appl Microbiol Biotechnol 92:1–11. http://dx.doi.org
/10.1007/s00253-011-3486-x.
56. Jaeger T, Mayer C. 2008. N-acetylmuramic acid 6-phosphate lyases
(MurNAc etherases): role in cell wall metabolism, distribution, structure,
and mechanism. Cell Mol Life Sci 65:928 –939. http://dx.doi.org/10.1007
/s00018-007-7399-x.
57. Hadi T, Hazra S, Tanner ME, Blanchard JS. 2013. Structure of MurNAc
6-phosphate hydrolase (MurQ) from Haemophilus influenzae with a
bound inhibitor. Biochemistry 52:9358 –9366. http://dx.doi.org/10.1021
/bi4010446.
58. Wright JS, III, Jin R, Novick RP. 2005. Transient interference with
staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad
Sci U S A 102:1691–1696. http://dx.doi.org/10.1073/pnas.0407661102.
59. Wang R, Braughton KR, Kretschmer D, Bach THL, Queck SY, Li M,
Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, Deleo FR, Otto
M. 2007. Identification of novel cytolytic peptides as key virulence deter-
minants for community-associated MRSA. Nat Med 13:1510 –1514. http:
//dx.doi.org/10.1038/nm1656.
60. Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner
DJ, Long D, Bubeck Wardenburg J, Schneewind O, Otto M, Deleo FR.
2011. Comparative analysis of USA300 virulence determinants in a rabbit
model of skin and soft tissue infection. J Infect Dis 204:937–941. http://dx
.doi.org/10.1093/infdis/jir441.
61. Anwar S, Prince LR, Foster SJ, Whyte MK, Sabroe I. 2009. The rise and
rise of Staphylococcus aureus: laughing in the face of granulocytes. Clin
Exp Immunol 157:216 –224. http://dx.doi.org/10.1111/j.1365-2249.2009
.03950.x.
62. Foster TJ. 2005. Immune evasion by staphylococci. Nat Rev Microbiol
3:948 –958. http://dx.doi.org/10.1038/nrmicro1289.
63. Zecconi A, Scali F. 2013. Staphylococcus aureus virulence factors in eva-
sion from innate immune defenses in human and animal diseases. Immu-
nol Lett 150:12–22. http://dx.doi.org/10.1016/j.imlet.2013.01.004.
64. Diep BA, Otto M. 2008. The role of virulence determinants in commu-
nity-associated MRSA pathogenesis. Trends Microbiol 16:361–369. http:
//dx.doi.org/10.1016/j.tim.2008.05.002.
65. Gordon RJ, Lowy FD. 2008. Pathogenesis of methicillin-resistant Staph-
ylococcus aureus infection. Clin Infect Dis 46(Suppl 5):S350 –S359. http:
//dx.doi.org/10.1086/533591.
66. Berube BJ, Wardenburg JB. 2013. Staphylococcus aureus 	-toxin: nearly a
century of intrigue. Toxins (Basel) 5:1140 –1166. http://dx.doi.org/10
.3390/toxins5061140.
67. Muñoz-Planillo R, Franchi L, Miller LS, Nuñez G. 2009. A critical role
for hemolysins and bacterial lipoproteins in Staphylococcus aureus-
induced activation of the Nlrp3 inflammasome. J Immunol 183:3942–
3948. http://dx.doi.org/10.4049/jimmunol.0900729.
68. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-
Tekippe E, Ting JP, Duncan JA. 2009. Staphylococcus aureus alpha-
hemolysin activates the NLRP3-inflammasome in human and mouse
monocytic cells. PLoS One 4:e7446. http://dx.doi.org/10.1371/journal
.pone.0007446.
69. Bubeck Wardenburg J, Schneewind O. 2008. Vaccine protection against
Staphylococcus aureus pneumonia. J Exp Med 205:287–294. http://dx.doi
.org/10.1084/jem.20072208.
70. National Institute of Allergy and Infectious Diseases. 2014. NIAID’s anti-
bacterial resistance program: current status and future directions. National
Institute of Allergy and Infectious Diseases, Bethesda, MD. http://
www.niaid.nih.gov/topics/antimicrobialresistance/documents
/arstrategicplan2014.pdf.
71. Cech NB, Horswill AR. 2013. Small-molecule quorum quenchers to
prevent Staphylococcus aureus infection. Future Microbiol 8:1511–1514.
http://dx.doi.org/10.2217/fmb.13.134.
72. Kaufmann GF, Park J, Janda KD. 2008. Bacterial quorum sensing: a new
target for anti-infective immunotherapy. Expert Opin Biol Ther 8:719 –
724. http://dx.doi.org/10.1517/14712598.8.6.719.
73. Njoroge J, Sperandio V. 2009. Jamming bacterial communication: new
approaches for the treatment of infectious diseases. EMBO Mol Med
1:201–210. http://dx.doi.org/10.1002/emmm.200900032.
74. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney
AR, Braughton KR, Schneewind O, DeLeo FR. 2010. Targeting of alpha-
hemolysin by active or passive immunization decreases severity of
USA300 skin infection in a mouse model. J Infect Dis 202:1050 –1058.
http://dx.doi.org/10.1086/656043.
75. Sampedro GR, DeDent AC, Becker RE, Berube BJ, Gebhardt MJ, Cao
H, Bubeck Wardenburg J. 2014. Targeting Staphylococcus aureus alpha-
toxin as a novel approach to reduce severity of recurrent skin and soft-
tissue infections. J Infect Dis 210:1012–1018. http://dx.doi.org/10.1093
/infdis/jiu223.
76. Tkaczyk C, Hamilton MM, Datta V, Yang XP, Hilliard JJ, Stephens GL,
Sadowska A, Hua L, O’Day T, Suzich J, Stover CK, Sellman BR. 2013.
Staphylococcus aureus alpha toxin suppresses effective innate and adaptive
immune responses in a murine dermonecrosis model. PLoS One
8:e75103. http://dx.doi.org/10.1371/journal.pone.0075103.
77. Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lind-
berg FP. 2000. Survival of Staphylococcus aureus inside neutrophils con-
tributes to infection. J Immunol 164:3713–3722. http://dx.doi.org/10
.4049/jimmunol.164.7.3713.
78. Voyich JA, Braughton KR, Sturdevant DE, Whitney AR, Said-Salim B,
Porcella SF, Long RD, Dorward DW, Gardner DJ, Kreiswirth BN,
Musser JM, DeLeo FR. 2005. Insights into mechanisms used by Staphy-
lococcus aureus to avoid destruction by human neutrophils. J Immunol
175:3907–3919. http://dx.doi.org/10.4049/jimmunol.175.6.3907.
79. Greenlee-Wacker MC, Rigby KM, Kobayashi SD, Porter AR, DeLeo FR,
Nauseef WM. 2014. Phagocytosis of Staphylococcus aureus by human neu-
trophils prevents macrophage efferocytosis and induces programmed ne-
crosis. J Immunol 192:4709 – 4717. http://dx.doi.org/10.4049/jimmunol
.1302692.
80. Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B,
Golda A, Maciag-Gudowska A, Brix K, Shaw L, Foster T, Potempa J.
2008. A potential new pathway for Staphylococcus aureus dissemination:
the silent survival of S. aureus phagocytosed by human monocyte-derived
macrophages. PLoS One 3:e1409. http://dx.doi.org/10.1371/journal.pone
.0001409.
81. Nygaard TK, Pallister KB, DuMont AL, DeWald M, Watkins RL,
Pallister EQ, Malone C, Griffith S, Horswill AR, Torres VJ, Voyich JM.
2012. Alpha-toxin induces programmed cell death of human T cells, B
cells, and monocytes during USA300 infection. PLoS One 7:e36532. http:
//dx.doi.org/10.1371/journal.pone.0036532.
82. Cho JS, Guo Y, Ramos RI, Hebroni F, Plaisier SB, Xuan C, Granick JL,
Matsushima H, Takashima A, Iwakura Y, Cheung AL, Cheng G, Lee DJ,
Simon SI, Miller LS. 2012. Neutrophil-derived IL-1 is sufficient for abscess
formation in immunity against Staphylococcus aureus in mice. PLoS Pathog
8:e10003047. http://dx.doi.org/10.1371/journal.ppat.1003047.
83. Rigby KM, DeLeo FR. 2012. Neutrophils in innate host defense against
Staphylococcus aureus infections. Semin Immunopathol 34:237–259. http:
//dx.doi.org/10.1007/s00281-011-0295-3.
84. Miller LS, Pietras EM, Uricchio LH, Hirano K, Rao S, Lin H, O’Connell
RM, Iwakura Y, Cheung AL, Cheng G, Modlin RL. 2007. Inflam-
masome-mediated production of IL-1beta is required for neutrophil re-
cruitment against Staphylococcus aureus in vivo. J Immunol 179:6933–
6942. http://dx.doi.org/10.4049/jimmunol.179.10.6933.
85. Otto M. 2012. Molecular basis of Staphylococcus epidermidis infections.
Semin Immunopathol 34:201–214. http://dx.doi.org/10.1007/s00281-011
-0296-2.
86. Yao Y, Vuong C, Kocianova S, Villaruz AE, Lai Y, Sturdevant DE, Otto
M. 2006. Characterization of the Staphylococcus epidermidis accessory-
gene regulator response: quorum-sensing regulation of resistance to hu-
man innate host defense. J Infect Dis 193:841– 848. http://dx.doi.org/10
.1086/500246.
87. Lina G, Boutite F, Tristan A, Bes M, Etienne J, Vandenesch F. 2003.
Bacterial competition for human nasal cavity colonization: role of staph-
ylococcal agr alleles. Appl Environ Microbiol 69:18 –23. http://dx.doi.org
/10.1128/AEM.69.1.18-23.2003.
88. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, Kastenmuller
W, Deming C, Quinones M, Koo L, Conlan S, Spencer S, Hall JA,
Daly et al.
2234 aac.asm.org April 2015 Volume 59 Number 4Antimicrobial Agents and Chemotherapy
 on A


































Dzutsev A, Kong H, Campbell DJ, Trinchieri G, Segre JA, Belkaid Y.
2012. Compartmentalized control of skin immunity by resident commen-
sals. Science 337:1115–1119. http://dx.doi.org/10.1126/science.1225152.
89. Nakamizo S, Egawa G, Honda T, Nakajima S, Belkaid Y, Kabashima K.
2015. Commensal bacteria and cutaneous immunity. Semin Immuno-
pathol 37:73– 80. http://dx.doi.org/10.1007/s00281-014-0452-6.
90. Otto M, Echner H, Voelter W, Gotz F. 2001. Pheromone cross-
inhibition between Staphylococcus aureus and Staphylococcus epidermidis.
Infect Immun 69:1957–1960. http://dx.doi.org/10.1128/IAI.69.3.1957
-1960.2001.
91. Otto M, Sussmuth R, Vuong C, Jung G, Gotz F. 1999. Inhibition of
virulence factor expression in Staphylococcus aureus by the Staphylococcus
epidermidis agr pheromone and derivatives. FEBS Lett 450:257–262. http:
//dx.doi.org/10.1016/S0014-5793(99)00514-1.
92. Wright, JS, III, Jin R, Novick RP. 2005. Transient interference with
staphylococcal quorum sensing blocks abscess formation. Proc Natl Acad
Sci U S A 102:1691–1696. http://dx.doi.org/10.1073/pnas.0407661102.
93. Luo M, Qiu J, Zhang Y, Wang J, Dong J, Li H, Leng B, Zhang Q, Dai
X, Niu X, Zhao S, Deng X. 2012. 	-Cyperone alleviates lung cell injury
caused by Staphylococcus aureus via attenuation of alpha-hemolysin ex-
pression. J Microbiol Biotechnol 22:1170 –1176. http://dx.doi.org/10
.4014/jmb.1202.02017.
94. Nakayama J, Uemura Y, Nishiguchi K, Yoshimura N, Igarashi Y,
Sonomoto K. 2009. Ambuic acid inhibits the biosynthesis of cyclic pep-
tide quormones in Gram-positive bacteria. Antimicrob Agents Che-
mother 53:580 –586. http://dx.doi.org/10.1128/AAC.00995-08.
95. Cech NB, Junio HA, Ackermann LW, Kavanaugh JS, Horswill AR.
2012. Quorum quenching and antimicrobial activity of goldenseal (Hy-
drastis canadensis) against methicillin-resistant Staphylococcus aureus
(MRSA). Planta Med 78:1556 –1561. http://dx.doi.org/10.1055/s-0032
-1315042.
96. Quave CL, Plano LR, Bennett BC. 2011. Quorum sensing inhibitors of
Staphylococcus aureus from Italian medicinal plants. Planta Med 77:188 –
195. http://dx.doi.org/10.1055/s-0030-1250145.
97. National Research Council. 2011. Guide for the care and use of laboratory
animals: 8th ed. National Academies Press, Washington, DC.
Natural Product Limits of S. aureus Virulence
April 2015 Volume 59 Number 4 aac.asm.org 2235Antimicrobial Agents and Chemotherapy
 on A
ugust 14, 2015 by U
N
IV
 O
F
 N
O
R
T
H
 C
A
R
O
LIN
A
 A
T
 G
R
E
E
N
S
B
O
R
O
http://aac.asm
.org/
D
ow
nloaded from
 
